

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal

Lenalidomide for the treatment of newly diagnosed multiple myeloma

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Celgene (lenalidomide) <p><u>Patient/carer group</u></p> <ul style="list-style-type: none"> • Afiya Trust • African Caribbean Leukaemia Trust • Anthony Nolan Bone Marrow Trust • Black Health Agency • CANCERactive • Cancer Black Care • Cancer Equality • Cancer 52 • Chinese National Healthy Living Centre • Counsel and Care • Equalities National Council • Helen Rollason Heal Cancer Charity • Leukaemia CARE • Leukaemia Society (UK) • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Britain • Muslim Health Network • Myeloma UK • Rarer Cancers Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder Care • Tenovus <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Association for Services to the Elderly 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association for Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • NHS Quality Improvement Scotland • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> • Actavis UK (prednisolone) • Alliance Pharmaceuticals (prednisolone) • Amdipharm (prednisolone) • Aspen Europe (melphalan) • Auden McKenzie (Pharma Division) (dexamethasone) • Baxter Healthcare (cyclophosphamide) • Celgene (thalidomide) • Essential Generics (dexamethasone) • GlaxoSmithKline (melphalan) • Janssen–Cilag (bortezomib) • Merck Sharp & Dohme (dexamethasone) • Pfizer (cyclophosphamide,

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Committee for Standards in Haematology • British Geriatrics Society • British Oncological Association (BOA) • British Psychosocial Oncology Society • British Society for Haematology • British Society of Blood and Bone Marrow Transplantation • British Transplantation Society • Cancer Networks Pharmacists Forum • Cancer Research UK • NHS Blood and Transplant • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Myeloma Forum • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Abertawe Bro Morgannwg University Health Board • Department of Health • NHS North Staffordshire • Welsh Assembly Government 	<p>methylprednisolone)</p> <ul style="list-style-type: none"> • Rosemont Pharmaceuticals (dexamethasone) • Sigma Pharmaceuticals (methylprednisolone) • Winthrop Pharmaceuticals UK (prednisolone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Clinical Trials Research Unit (CTRU), University of Leeds • Cochrane Haematology Malignancies Group • Elimination of Leukaemia Fund • Institute of Cancer Research • Leukaemia and Lymphoma Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Evidence Review Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • tbc

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important

organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government; relevant NHS organisations in England and local health boards in Wales.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and consultee organisations representing patient/carers and professionals can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.